Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- Home

Blood pressure

10 findings across 8 drug records. Domain pages are descriptive indexes, not advice.

Most represented records

CagriSema (2)

Survodutide (2)

Orforglipron (1)

Retatrutide (1)

Semaglutide (1)

Evidence spread

High evidence 1 Moderate evidence 5 Low evidence 3 Very low evidence 1

CagriSema INVESTIGATIONAL
Blood pressure Decrease
Low evidence

CagriSema reduced SBP versus placebo and versus semaglutide alone in REDEFINE 1.

REDEFINE 1 BP analysis, Hypertension, 2025/2026 Source
PopulationAdults without diabetes, BMI >=30 or >=27 + complication; REDEFINE 1 phase 3a; 68 weeks.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsDOI from publisher page, not PubMed-verified - identifier needs confirmation.
Comparatorssemaglutide 2.4 mg; cagrilintide 2.4 mg; placebo
Orforglipron INVESTIGATIONAL
Blood pressure Decrease
Moderate evidence

Orforglipron produced significant placebo-adjusted BP decreases in phase 2 T2D and obesity; plateau at >=12 mg.

Wharton S et al., Cardiovasc Diabetol, 2025;24(1):240 Source
PopulationPhase 2 pooled: T2D N=361 (26 wk) and obesity N=234 (36 wk); orforglipron 3-45 mg vs placebo (+dulaglutide in T2D).
Fundingindustry - Eli Lilly and Company
Scope limitssurrogate/exploratory endpoint
Comparatorsplacebo; dulaglutide 1.5 mg (T2D study)
Retatrutide INVESTIGATIONAL
Blood pressure Decrease
Moderate evidence

Retatrutide lowered SBP/DBP dose-dependently (exploratory) in phase 2 obesity.

Jastreboff AM et al. (retatrutide phase 2), NEJM, 2023;389:514-526 Source
PopulationN=338 adults with obesity; retatrutide 1-12 mg vs placebo; 48 weeks; phase 2 (NCT04881760).
Fundingindustry-Eli Lilly
Scope limitsconference/abstract-level; magnitude web/secondary-sourced; surrogate/exploratory endpoint
Comparatorsplacebo
Semaglutide MARKETED
Blood pressure Decrease
Low evidence

Once-weekly semaglutide 2.4 mg reduced office SBP/DBP versus placebo across the STEP 1-5 programme.

Amaro A et al. (STEP cardiometabolic review), Postgrad Med, 2022;134(sup1):18-27 Source
PopulationAdults with overweight/obesity, STEP 1-5; most 68 weeks; RCT.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsReview summary, not a dedicated ABPM trial. Magnitude approximate; confirm against individual STEP papers. PMID/DOI verified.
Comparatorsplacebo
Survodutide INVESTIGATIONAL
Blood pressure Decrease
Low evidence

Survodutide reduced blood pressure (with waist circumference and triglycerides) in phase 2 obesity cardiometabolic analysis.

Survodutide phase 2 cardiometabolic, Eur Heart J, 2024;45(Suppl 1):ehae666.2895 Source
PopulationN=387 adults BMI >=27 without diabetes; survodutide 0.6-4.8 mg vs placebo; 46 weeks; phase 2.
Fundingindustry - Boehringer Ingelheim / Zealand (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level
Comparatorsplacebo
Tirzepatide MARKETED
Blood pressure Decrease
High evidence

Tirzepatide reduced 24-hour ambulatory systolic BP versus placebo (SURMOUNT-1 ABPM substudy); effect partly weight-mediated.

de Lemos JA et al. (SURMOUNT-1 ABPM), Hypertension, 2024;81(4):e41-e43 Source
PopulationN=600 adults BMI >=27, BP <140/90 on stable antihypertensives, SURMOUNT-1 substudy; 36 weeks; RCT.
Fundingindustry - Eli Lilly
Scope limitsmagnitude web/secondary-sourced
Comparatorsplacebo
CagriSema INVESTIGATIONAL
Blood pressure Decrease
Moderate evidence

Clinically relevant BP reductions including in resistant hypertension (REDEFINE 1 post hoc)

Verma S et al. Hypertension 2025;83:e26055 Source
PopulationObese/overweight no diabetes (n=3417), phase 3a post hoc, 68 wk
Fundingindustry-Novo Nordisk
Scope limitspost-hoc (not prespecified)
Comparatorsplacebo; semaglutide 2.4 mg; cagrilintide 2.4 mg
Mazdutide INVESTIGATIONAL
Blood pressure Decrease
Moderate evidence

Mazdutide reduced systolic blood pressure vs placebo (GLORY-1)

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationChinese overweight/obese (n=610), phase 3 GLORY-1, 48 wk
FundingInnovent Biologics
Scope limitsBP magnitude press-derived; flag unconfirmed pending full-text (Re-pointed 2026-06-23 from duplicate press/registry row to published GLORY-1 source PMID40421736; press-derived caveat retained.)
Comparatorsplacebo
Pemvidutide INVESTIGATIONAL
Blood pressure Decrease
Very low evidence

Improvements in blood pressure without meaningful heart-rate increase or cardiac/arrhythmia imbalance

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM obesity phase 2 (n=391), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Scope limitsconference/abstract-level; identifier not fully verified; no outcome data yet (ongoing); small sample (N~50)
Comparatorsplacebo
Survodutide INVESTIGATIONAL
Blood pressure Decrease
Moderate evidence

Placebo-corrected reductions in systolic and diastolic BP at 4.8 mg

le Roux CW et al. Diabetes Obes Metab 2025 (post hoc, DOI 10.1111/dom.16052) Source
PopulationAdults with obesity, phase 2 post hoc analysis (n=387), 46 wk
Fundingindustry - Novo Nordisk (trial sponsor)
Scope limitspost-hoc (not prespecified)
Comparatorsplacebo